The global minimal residual disease (MRD) testing market size was valued at USD 2,210.5 million in 2024 and is projected to reach USD 2,850.0 million by 2026 and USD 9,650.0 million by 2036, growing at a CAGR of 13.0% from 2026 to 2036. This rapid expansion is primarily driven by the increasing prevalence of cancer, particularly hematological malignancies and solid tumors, alongside a paradigm shift toward personalized medicine. MRD testing has emerged as a critical tool in oncology for monitoring treatment response, detecting early relapse, and guiding clinical decision-making. The integration of high-sensitivity technologies such as Next-Generation Sequencing (NGS) and digital Polymerase Chain Reaction (dPCR) has significantly enhanced the precision of detecting trace amounts of cancer cells that remain in a patient’s body after treatment.
The evolution of oncology from a one-size-fits-all approach to precision medicine has placed MRD testing at the forefront of clinical practice. Minimal residual disease refers to the small number of cancer cells that remain in the patient during or after treatment when the patient is in clinical remission. These cells are the primary cause of cancer relapse. Traditional imaging and microscopic methods lack the sensitivity to detect these cells, whereas molecular MRD testing can identify one cancer cell among a million healthy cells. This capability allows clinicians to identify patients who may need intensified therapy or those who can safely de-escalate treatment, thereby reducing toxicity and healthcare costs.
Despite the promising growth, the market faces hurdles related to the standardization of testing protocols and high costs associated with NGS-based assays. The complexity of interpreting genomic data requires specialized bioinformatics expertise, which may limit adoption in smaller clinical settings. Furthermore, reimbursement landscapes vary significantly across regions, often lagging behind the rapid pace of technological innovation. However, as clinical evidence continues to mount demonstrating the survival benefits of MRD-guided therapy, regulatory bodies and payers are increasingly recognizing the value of these tests, paving the way for broader market penetration.
The expansion into solid tumors represents the next frontier for the MRD testing market. While MRD has been the standard of care in leukemia and lymphoma for years, its application in breast, lung, and colorectal cancers is accelerating. The development of tumor-informed assays, which track patient-specific mutations identified from the primary tumor, has shown remarkable accuracy in predicting recurrence months before conventional imaging. This proactive approach is expected to revolutionize post-surgical management and adjuvant therapy selection, providing a substantial boost to market revenue over the forecast period.
The global minimal residual disease testing market is characterized by a high degree of innovation and a moderate level of consolidation. A few dominant players with proprietary NGS platforms and validated clinical assays hold significant market power. Companies such as Adaptive Biotechnologies, Natera, and Guardant Health have established strong footprints through extensive clinical validation studies and early-mover advantages. However, the market remains dynamic with the entry of established diagnostic giants like Roche and Illumina, who are leveraging their existing laboratory networks to offer MRD solutions. The competitive landscape is shaped by technological superiority, the breadth of the clinical evidence portfolio, and the ability to secure favorable reimbursement terms.
Market characteristics also include a heavy emphasis on research and development. Companies are investing heavily in improving the limit of detection (LoD) and reducing turnaround times. The integration of artificial intelligence and machine learning into bioinformatics pipelines is another defining feature, helping to filter out sequencing noise and identify true positive signals in cell-free DNA (cfDNA). Additionally, the market is seeing a trend toward ‘tumor-naive’ assays that do not require a tissue biopsy, offering a faster and more flexible alternative for patients where tissue samples are unavailable or insufficient.
The Next-Generation Sequencing (NGS) segment accounted for the largest revenue share in 2024 and is expected to maintain its dominance through 2036. NGS technology offers unparalleled sensitivity and the ability to monitor a broad spectrum of clones, making it ideal for the heterogeneous nature of many cancers. The ability of NGS to provide a comprehensive view of the clonal evolution of a tumor allows for the detection of emergent resistant mutations, which is critical for adjusting treatment strategies. As sequencing costs continue to decline and automated workflows become more common, NGS-based MRD testing is becoming more accessible to diagnostic laboratories worldwide.
The Polymerase Chain Reaction (PCR) segment, particularly digital PCR (dPCR) and quantitative PCR (qPCR), remains a vital component of the market. PCR-based methods are generally faster and more cost-effective than NGS, making them suitable for monitoring specific, well-defined mutations such as BCR-ABL1 in chronic myeloid leukemia. Digital PCR, in particular, offers absolute quantification and high sensitivity without the need for standard curves, bridging the gap between traditional qPCR and NGS. While it may not offer the multi-target capabilities of NGS, its ease of use and lower infrastructure requirements ensure its continued relevance in routine clinical monitoring.
Flow Cytometry is another established technology used primarily in hematological malignancies. Multiparametric flow cytometry (MFC) allows for the rapid identification of abnormal immunophenotypes. While historically less sensitive than molecular methods, recent advancements in ‘next-generation flow’ have significantly improved detection limits. MFC remains favored in many clinical settings due to its rapid turnaround time and ability to provide results within hours, which is crucial for acute clinical management decisions.
Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, currently lead the application segment. In these diseases, MRD status is often used as a primary endpoint in clinical trials and is increasingly incorporated into official treatment guidelines. For instance, in multiple myeloma, achieving MRD negativity is strongly correlated with prolonged progression-free survival and overall survival. The well-defined nature of genetic markers in blood cancers has facilitated the early development and adoption of highly sensitive MRD assays in this space.
The solid tumors segment is projected to grow at the fastest CAGR during the forecast period. The application of MRD testing in solid tumors, often referred to as molecular residual disease, involves the detection of circulating tumor DNA (ctDNA) after surgery or definitive therapy. In colorectal cancer, for example, MRD testing is being used to identify patients who are at high risk of recurrence and may benefit from adjuvant chemotherapy, while sparing low-risk patients from unnecessary treatment. Similar applications are being explored in breast, lung, and bladder cancers, representing a massive untapped market opportunity as these tests move from research settings into standard clinical practice.
North America held the largest market share in 2024, driven by a sophisticated oncology care model and a strong presence of leading diagnostic companies. The United States, in particular, has seen rapid adoption of MRD testing due to favorable Medicare coverage determinations for several NGS-based assays. The presence of major research institutions and a high volume of clinical trials involving MRD endpoints further solidify the region’s leadership. Additionally, high healthcare expenditure and a proactive approach to adopting precision medicine contribute to the robust market growth in this region.
Europe is the second-largest market, characterized by a strong emphasis on evidence-based medicine and a well-regulated diagnostic environment. Countries like Germany, France, and the UK are at the forefront of integrating molecular diagnostics into national cancer care programs. The transition to the In Vitro Diagnostic Regulation (IVDR) is expected to harmonize testing standards across the continent, although it may present short-term compliance challenges for some manufacturers. The European market benefits from collaborative research networks that facilitate large-scale clinical studies on the utility of MRD testing.
The Asia Pacific region is expected to experience the fastest growth through 2036. This is attributed to the rising incidence of cancer, increasing healthcare investments, and the expansion of diagnostic laboratory chains in countries like China and India. Government initiatives to improve cancer screening and management, coupled with a growing middle class with access to advanced medical technologies, are driving demand. Furthermore, many global players are expanding their geographic footprint in Asia Pacific through local partnerships and the establishment of regional reference labs to cater to the diverse patient populations.
The market features a mix of specialized molecular diagnostic firms and large diversified healthcare corporations. The following are the leading companies in the minimal residual disease testing market:
Adaptive Biotechnologies is a pioneer in the field with its clonoSEQ assay, the first FDA-cleared NGS-based test for MRD in certain blood cancers. The company focuses on the immune system’s genetic code to develop clinical products for the diagnosis and monitoring of disease. Natera, Inc. has made significant strides in the solid tumor space with its Signatera test, a personalized, tumor-informed assay that has received multiple Breakthrough Device Designations from the FDA. Guardant Health is another key player, known for its Guardant Reveal test, which focuses on a tumor-naive approach for detecting residual disease in early-stage cancers through blood samples.
| Report Attribute | Details |
| Market size value in 2026 | USD 2,850.0 million |
| Revenue forecast in 2036 | USD 9,650.0 million |
| Growth rate | CAGR of 13.0% from 2026 to 2036 |
| Base year for estimation | 2025 |
| Historical data | 2020 – 2024 |
| Forecast period | 2026 – 2036 |
| Quantitative units | Revenue in USD million and CAGR from 2026 to 2036 |
| Report coverage | Revenue forecast, competitive landscape, growth factors, and trends |
| Segments covered | Technology, Application, End-user, Region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Argentina; Saudi Arabia; South Africa |
| Key companies profiled | Adaptive Biotechnologies; Natera; Guardant Health; Roche; Illumina; Qiagen; Thermo Fisher Scientific; NeoGenomics; Invitae; Sysmex; Bio-Rad; Exact Sciences |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2026 to 2036.
Technology Outlook (Revenue, USD Million, 2026 – 2036)
Application Outlook (Revenue, USD Million, 2026 – 2036)
End-user Outlook (Revenue, USD Million, 2026 – 2036)
Region Outlook (Revenue, USD Million, 2026 – 2036)
The global minimal residual disease testing market size was estimated at USD 2,210.5 million in 2024 and is expected to reach USD 2,850.0 million in 2026.
The market is expected to grow at a compound annual growth rate of 13.0% from 2026 to 2036, reaching a value of USD 9,650.0 million by 2036.
Next-Generation Sequencing (NGS) is expected to lead the market due to its high sensitivity and ability to detect multiple genetic alterations simultaneously.
Key drivers include the rising global cancer burden, the shift toward personalized oncology, technological advancements in liquid biopsies, and the increasing use of MRD as a clinical trial endpoint.
North America accounted for the largest revenue share in 2024, driven by advanced diagnostic infrastructure and favorable reimbursement policies in the United States.
Tumor-informed tests use the patient’s primary tumor tissue to identify specific mutations to track, while tumor-naive tests look for common cancer markers without requiring a prior tissue sample.
In solid tumors, MRD testing is primarily used after surgery to detect circulating tumor DNA, which indicates a high risk of recurrence and helps guide the use of adjuvant therapy.
Key players include Adaptive Biotechnologies, Natera, Guardant Health, Roche, Illumina, and NeoGenomics, among others.
Challenges include high costs of NGS testing, lack of standardized protocols across different laboratories, and varying reimbursement landscapes globally.
